FreshPatents.com Logo


new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)


Similar
Filing Names

Glaxo Group Limited
Glaxo Group Limited A Corporation

Popular
Companies


Web
Adobe patents
Amazon patents
Apple patents
Ebay patents
Facebook patents
Google patents
IBM patents
Linkedin patents
Microsoft patents
Oracle patents
Red Hat patents
Yahoo patents

Food/Health
Adidas
Nike patents
Pfizer patents
Monsanto patents
Medtronic patents
Kraft patents

Transportation
Boeing patents
Tesla Motors patents

Telecom
Qualcomm patents
Motorola patents
Nokia patents
RIMM patents

Industrial/Electronics
AMD
Applied Materials
Seagate patents
General Electric
Caterpillar patents
Samsung
Wal-mart patents

Glaxo Group Limited patents


      
Recent patent applications related to Glaxo Group Limited. Glaxo Group Limited is listed as an Agent/Assignee. Note: Glaxo Group Limited may have other listings under different names/spellings. We're not affiliated with Glaxo Group Limited, we're just tracking patents.

ARCHIVE: New 2015 2014 2013 2012 2011 2010 2009 | Company Directory "G" | Glaxo Group Limited-related inventors


Search recent Press Releases: Glaxo Group Limited-related press releases
Count Application # Date Glaxo Group Limited patents (updated weekly) - BOOKMARK this page
12015010538704/16/15 new patent  Substituted diketopiperazines and their use as oxytocin antagonists
22015009975604/09/15Pyrimidinone compounds for use in the treatment of diseases or conditions mediated by lp-pla2
32015009341404/02/15Modified antigens
42015009344004/02/15Aggregate nanoparticulate medicament formulations, manufacture and use thereof
52015008034303/19/15Benzofuran compounds for the treatment of hepatitis c virus infections
62015008036903/19/15Novel compounds
72015006420103/05/15Antigen binding proteins to oncostatin m (osm)
82015006550703/05/15Novel compounds
92015004537502/12/15Novel compounds
102015000410501/01/15Novel composition
112014037848712/25/14Tricyclic compounds, preparation methods, and their uses
122014037126412/18/14Muscarinic acetylcholine receptor antagonists
132014033508311/13/14Methods of treatment and prevention of eye diseases
142014031197710/23/14Use of organic solvent nanofiltration and liquid-liquid chromatography for the recovery of pharmaceutical products
152014028813309/25/143 -amino- pyrazole derivatives useful against tuberculosis
162014022725908/14/14Modified proteins and peptides
172014022726408/14/14Drug fusions and conjugates with extended half life
182014020560407/24/14Antigen binding constructs
192014020566107/24/14Formulation for retinoid-containing soft gelatin capsules
202014020021807/17/14Novel crystalline forms of (3r, 6r)-3-(2,3-dihydro-1h-inden-2-yl)-1-[(1r)-1-(2,6-dimethyl-3-pyridinyl)-2-(4-morpholinyl)-2-oxoethyl]-6-[(1s)-1-methylpropyl]-2,5-piperazinedione
212014019340707/10/14Drug fusions and conjugates
222014018775007/03/14Methods for selecting protease resistant polypeptides
232014017971506/26/142,3-dihydroimidazo[1 ,2-c] pyrimidin-5(1 h)-one compounds use as lp-pla2 inhibitors
242014015870406/12/14Medicament dispenser
252014014099605/22/14Anti-serum albumin biding variable domains
262014011643405/01/14Dry powder inhaler compositions
272014011292904/24/14Tumour necrosis factor receptor 1 antagonists
282014011388804/24/14Novel combination of therapeutic agents
292014011392204/24/14Compounds
302014010589404/17/14Humanized anti-il-18 antibodies
312014010591504/17/14Bcma (cd269/tnfrsf17) - binding proteins
322014007631403/20/14Manifold for use in medicament dispenser
332014008086303/20/14Muscarinic acetylcholine receptor antagonists
342014005690002/27/14Method for inhibiting binding to b-cell receptor
352014005810502/27/14Substituted diketopiperazines and their use as oxytocin antagonists
362014005071902/20/14Antibodies
372014005172002/20/14N-cyclobutyl - imidazopyridine - methylamine as trpv1 antagonists
382014003898902/06/14Tetrahydropyrazolo [1,5-a] pyrimidine as anti-tuberculosis compounds
392014002359601/23/14Novel composition
402014002455801/23/14Method of treatment
412014000517701/02/14Pyridinyl- and pyrazinyl-methyloxy-aryl derivatives useful as inhibitors of spleen tyrosine kinase (syk)
422014000518801/02/14Pyrido[3,4-b]pyrazine derivatives as syk inhibitors
432013034546512/26/13Process for the preparation of retigabine
442013033698912/19/13Methods of identifying a patient population
452013031590111/28/13Novel uses
462013031704111/28/13Compounds
472013031028111/21/13Novel antigen binding proteins
482013030233511/14/13Ligands that bind tgf-beta receptor ii
492013026771710/10/13Process for the preparation of atovaquone
502013026118510/03/13Benzamide derivatives as ep4 receptor agonists
512013025172409/26/13Antigen binding proteins to oncostatin m (osm)
522013025318809/26/13Novel compounds
532013023750109/12/13Benzofuran compounds for the treatment of hepatitis c virus infections
542013022420408/29/13Method of treatment based on atad2 inhibitors
552013021315408/22/13Method of determining cleanliness
562013021339408/22/13Dispensing device
572013021765808/22/13Pyrazole compounds acting against allergic, inflammatory and immune disorders
582013021089208/15/13Method of treatment
592013020370508/08/13Pyrazole compounds acting against allergic, immune and inflammatory conditions
602013020380208/08/133 -amino- pyrazole derivatives useful against tuberculosis
612013019641208/01/13Magi polynucleotides, polypetides, and antibodies
622013018925507/25/13Fusions and conjugates of insulinotropic agents
632013013133805/23/13Substituted diketopiperazines as oxytocin antagonists
642013011813205/16/13Machine and pharmaceutical and pharmaceutical-like product assembly
652013010969005/02/13Novel crystalline forms of (3r, 6r)-3-(2,3-dihydro-1h-inden-2-yl)-1-[(1r)-1-(2,6-dimethyl-3-pyridinyl)-2-(4-morpholinyl)-2-oxoethyl]-6-[(1s)-1-methylpropyl]-2,5-piperazinedione
662013010278304/25/13Substituted diketopiperazines and their use as oxytocin antagonists
672013007819803/28/13Novel use
682013005337502/28/13Amino-quinolines as kinase inhibitors
692013003947002/14/13Sample plate for an x-ray powder diffraction apparatus
702013004098402/14/137-(lh-pyrazol-4-yl)-1,6-naphthyridine compounds as syk inhibitors
712013003001201/31/13Compounds
722013003001501/31/13Muscarinic acetylcholine receptor antagonists
732013002354101/24/13Voltage-gated sodium channel blockers
742013001249101/10/13Pyrimidine derivatives for use as sphingosine 1-phosphate 1 (s1p1) receptor agonists
752012031620212/13/12Compounds which have activity at m1 receptor and their uses in medicine
762012030972512/06/12Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist
772012030978912/06/12Compounds which have activity at m1 receptor and their uses in medicine
782012028854411/15/12Novel retigabine composition
792012027727911/01/12Non-steroidal glucocorticoid inhibitors and their use in treating inflammation, allergy and auto-immune conditions
802012025146810/04/12Compositions comprising alginates with high guluronic acid/mannuronic acid ratio for use in the treatment of dentine hypersensitivity
812012024074209/27/12Novel device
822012024517109/27/12Benzpyrazole derivatives as inhibitors of pi3 kinases
832012023855909/20/12Novel compounds
842012023857109/20/12Indazole derivatives as pi 3-kinase
852012023206109/13/12Novel compounds
862012020774908/16/12Dosing regimen
872012020281108/09/12Novel compounds
882012015744606/21/12Medical use
892012015749106/21/12Muscarinic acetylcholine receptor antagonists
902012015749206/21/12Antibiotic drug
912012014971106/14/12Piperidine derivatives used as orexin antagonists
922012014973106/14/12New medical use
932012012868905/24/12Anti-il-23 immunoglobulins
942012012977805/24/12Ligand that bind tgf-beta receptor rii
952012011464705/10/12Anti-serum album single variable domains
962012010013704/26/12Immunoglobulins
972012010108304/26/12S1p1 agonists comprising a bicyclic n-containing ring
982012010108604/26/12Thiadiazole derivatives and their use for the treatment of disorders mediated by s1p1 receptors
992012010112404/26/121,2,4-oxadiazol derivatives, their pharmaceutical compositions and their use as sphingosine 1-phosphate 1 receptor agonists
1002012010113404/26/125-membered heteroaryl derivatives used as sphingosine 1-phosphate receptor agonists
1012012010113604/26/125-membered heteroaryl derivatives used as sphingosine 1- phosphate receptor agonists
1022012006517703/15/12Pharmaceutical formulations comprising azelastine and a corticosteroid for the treatment of inflammatory or allergic conditions
1032012005896303/08/12Macrolides with anti-inflammatory activity
1042012004625802/23/12Novel crystalline pharmaceutical product
1052012004646902/23/12Process for the preparation of a biphenyl-2-yl carbamic acid ester
1062012003982002/16/12Antibacterial composition comprising 4-isopropyl-3-methylphenol and zinc ions
1072012004099102/16/123-azabicyclo [4.1.0] heptanes used as orexin antagonists
1082012004102702/16/12Benzimidazoles which have activity at m1 receptor and their uses in medicine
1092012004102802/16/12Benzimidazoles which have activity at m1 receptor and their uses in medicine
1102012003431202/09/124-isopropyl-3-methylphenol for the treatment of inflammation
1112012000632201/12/12Drug dispenser
1122012000422901/05/12Substituted diketopiperazines and their use as oxytocin antagonists
1132011031937112/29/11Pharmaceutical formulations comprising 4-hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol
1142011030569212/15/11Antigen-binding contructs
1152011030569312/15/11Anitigen-binding constructs
1162011028809811/24/11Novel compounds
1172011028190911/17/11Substituted quinoline derivatives as h1 receptor antagonists
1182011027565511/10/11Pyrimidinecarboxamide derivatives as inhibitors of syk kinase
1192011027566111/10/11Tricyclic nitrogen compounds used as antibacterials
1202011026973811/03/11Compounds
1212011026997011/03/11Phenethanolamine derivatives for treatment of respiratory diseases
1222011026358810/27/11Tricyclic compounds as glutamate receptor modulators
1232011025375210/20/11Nozzle for a nasal inhaler
1242011025607410/20/11Novel use
1252011024547010/06/11Immunoglobulins
1262011023779209/29/11Quinoline derivatives and their use as 5-ht6 ligands
1272011019027408/04/11Salt of, and processes for the preparation of, 1-isopropyl-4-hexahydro-1h-1,4-diazepine
1282011017806307/21/11Benzpyrazol derivatives as inhibitors of pi3 kinases
1292011016615007/07/11Anhydrous crystal form of ovrepitant maleate
1302011015087106/23/11Treatment of an autoimmune disease using il-18 antagonists
1312011015226206/23/11Novel compounds
1322011014282406/16/11Antibodies against amyloid-beta peptide
1332011014415106/16/11Novel process, salts, composition and use
1342011013569506/09/11Oral dosage form for controlled drug release
1352011013042306/02/11Compounds which have activity at m1 receptor and their uses in medicine
1362011011719005/19/11Pharmaceutical formulations
1372011011826105/19/11Bis-pyridylpyridones as melanin-concentrating hormone receptor 1 antagonists
1382011006164603/17/11Drug dispenser
1392011006474003/17/11Antigen binding proteins
1402011006572503/17/11Triazole amide derivatives for use in therapy
1412011005916703/10/11Encapsulation of biologically active agents
1422011005997903/10/11Piperidine/cyclohexane carboxamide derivatives for use as vanilloid receptor modulators
1432011004502702/24/11Adjuvant
1442011004613702/24/11Pyrazole derivatives as p2x7 modulators
1452011003452402/10/11Hemi-fumarate salt of a 1,3,4-thiadiazolyl derivative as modulator of the sphingosine 1-phosphate receptor
1462011002157801/27/11Compounds which potentiate the ampa receptor and uses thereof in medicine
1472011000939401/13/11Tricyclic nitrogen compounds and their use as antibacterial agents
1482011000963101/13/11Phenethanolamine derivatives for treatment of respiratory diseases
1492010032999612/30/10Novel combination of therapeutic agents
1502010032402212/23/10Novel compounds
1512010031657912/16/10Novel use of alkyl phosphate esters
1522010031766612/16/10Composition comprising an nk-1 receptor antagonist and an ssri for the treatment of tinnitus and hearing loss
1532010031767212/16/10Monomaleate monohydrate salt of a 5ht1a receptor antagonist
1542010030808212/09/10Dispensing device
1552010031170612/09/10Method of treatment of allergic rhinitis
1562010031173412/09/10Spiro compounds useful as antagonists of the h1 receptor
1572010030382112/02/10Immunoglobulins
1582010030510712/02/10Quinoline derivatives and their use as 5-ht6 ligands
1592010030512712/02/10Novel compounds
1602010030516612/02/10Novel compounds
1612010029222411/18/10Isothiazolidine 1,1-dioxide and tetrahydro-2h-1,2-thiazine 1,1-dioxide derivatives as p2x7 modulators
1622010029229511/18/105-oxo-3-pyrrolidinecarboxamide derivatives as p2x7 modulators
1632010028615211/11/10N-phenyl hydrazides as modulators of the ghrelin receptor
1642010027590911/04/10Actuator for an inhaler
1652010027385310/28/10Novel isoindol derivatives as ep4 receptor agonists
1662010026769110/21/10Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
1672010026773410/21/10N-[(3,5-dichlorophenyl)methyl]-2-(4-methyl-1-piperazinyl)-2-(1-naphthalenyl)ethanamide as ghrelin receptor modulator
1682010025619910/07/10Crystalline form of an antimalarial compound
1692010025691910/07/10Methods for detecting lp-pla2 activity and inhibition of lp-pla2 activity
1702010023966609/23/10Process for producing mouldings from (meth) acrylate copolymers by means of injection moulding
1712010022418509/09/10Actuator for an inhaler
1722010022234909/02/10Quinoline derivatives used to treat inflammatory and allergic diseases
1732010021679908/26/10Phthalazine and pyrido[3,4-d]pyridazine compounds as h1 receptor antagonists
1742010021683708/26/10Glycine transport inhibitors
1752010021067208/19/10Azabicyclo [3. 1. o] hexyl derivatives as modulators of dopamine d3 receptors
1762010020325608/12/10Method and the application of powder material to substrates
1772010020424208/12/10Piperazine derivative having affinity for the histamine h3 receptor
1782010020427308/12/10Quinoline and quinazoline derivatives having affinity for 5ht1-type receptors
1792010019767908/05/10Compounds
1802010019769908/05/10I-oxa-3-azaspiro (4.5) decan-2-one and 1-oxa-3, 8-diazaspiro (4.5) decan-2-one derivatives for the treatment of eating disorders
1812010019076407/29/10Novel compounds
1822010018477007/22/10Compounds
1832010018499607/22/10Process of amide formation
1842010017569807/15/10Capsule
1852010017406507/08/10Compounds
1862010014809106/17/10Method and system for rapid phase luminescense spectroscopy analysis
1872010015219506/17/10Azabicyclo (3.1.0) hexane derivatives useful as modulators of dopamine d3 receptors
1882010014401606/10/10Apparatus for the disruption of animal cells
1892010014475506/10/10Novel compounds
1902010014482906/10/10Novel receptor antagonists and their methods of use
1912010014504006/10/10Benzazepine derivatives for the treatment of neurological disorders
1922010013727606/03/10Compounds which potentiate ampa receptor and uses thereof in medicine
1932010013735306/03/10Tricyclic compounds as antibacterials
1942010013737806/03/10Pyridine compounds for the treatment of prostaglandin mediated diseases
1952010013742806/03/10Oxygen containing heterocycles as glycine transporter inhibiting compounds
1962010013058305/27/10Prolinamide derivatives as modulators of voltage-gated sodium channels
1972010011352105/06/10Pharmaceutical compositions comprising 2-methoxy-5-(5-trifluoromethyl-tetrazol-1-yl-benzyl)-(2s-phenylpiperidin-3s-yl-)
1982010011352805/06/10Oxadiazole substituted indazole derivatives for use as sphingosine 1-phosphate (s1p) agonists
1992010011379605/06/10Indole derivatives as s1p1 receptor
2002010010565204/29/10Purines as cysteine protease inhibitors
2012010010568804/29/10Pharmaceutical compositions comprising 3,5-diamino-6-(2,3-dichlophenyl)-1,2,4-triazine or r(-)-2,4-diamino-5-(2,3-dichlorophenyl)-6-fluoromethyl pyrimidine and an nk1
2022010010575404/29/105-(4phenyl)prolinamide for treatment of epilepsy
2032010008742404/08/10Tricyclic nitrogen containing heterocycles as antibacterial agents
2042010008750204/08/10Indazoles used to treat estrogen receptor beta mediated disorders
2052010008766704/08/10Methods of synthesizing 1-(acyloxy)-alkyl carbamate prodrugs
2062010008183004/01/10Methods of synthesizing n-hydroxysuccinimidyl carbonates
2072010007595303/25/10Substituted piperazines, (1,4) diazepines, and 2,5-diazabicyclo (2.2.1) heptanes as histamine h1 and/or h3 antagonists or histamine h3 reverse antagonists
2082010007598203/25/10Pyridinone derivative for the treatment of premature ejaculation
2092010006816603/18/10Oral composition comprising dimethicone copolyol
2102010006940903/18/10"novel compounds"
2112010006941603/18/10Azabicyclo [3.1.0] hexyl derivatives as modulators of dopamine d3 receptors
2122010005905203/11/10Sheet driver for use in a drug dispenser
2132010006309703/11/10Azabicyclo [3.1.0] hexane derivatives as modulators of dopamine d3 receptors
2142010005650203/04/10Compounds
2152010005652703/04/10Benzofuran compounds useful in the treatment of conditions mediated by the action of pge2 at the ep1 receptor
2162010005659503/04/10Pyrazole derivatives as p2x7 modulators
2172010004863902/25/10Oxadiazole derivates as s1p1 receptor agonists
2182010004167202/18/10Use of quinoline derivatives in the treatment of pain and irritable bowel syndrome
2192010002969902/04/10Matrix metalloproteinase inhibitors
2202010001628701/21/10Compounds having affinity for dopamine d3 receptor and uses thereof"
2212010001637101/21/10Indole compounds
2222010001002101/14/10Novel compounds
2232010000052801/07/10Manifold for use in medicament dispenser
2242010000052901/07/10Manifold for use in medicament dispenser
2252010000342001/07/10Medicament dispenser
2262010000423001/07/10Azatricyclic compounds and their use
2272010000424001/07/10Indole compounds
2282009032595212/31/09Pyrazolo[3,4-b]pyridine compounds, and their use as pde4 inhibitors
2292009032603212/31/09Pharmaceutical compositions comprising nk1 receptor antagonists and sodium channel blockers
2302009031849412/24/09Pyrazolo[3,4-b]pyridine compounds, and their use as pde4 inhibitors
2312009031852312/24/09Benzoisoindole derivatives and their use as ep4 receptor agonists
2322009031853012/24/09Pharmaceutical compositions comprising nk1 receptor antagonists and sodium channel blockers
2332009031238812/17/09Benzo [f] isoindoles as ep4 receptor agonists
2342009031254612/17/09Quinoline and quinazoline derivatives having affinity for 5ht1-type receptors
2352009030605212/10/09Indenyl derivatives and use thereof for the treatment of neurological disorders
2362009029874212/03/09Process for manufacturing lactose
2372009029114611/26/09Process for manufacturing lactose
2382009029198711/26/09Novel polymorph of (5-amino-6-methoxy-3-pyridincarbonyl) carbamic acid 2-(s)-hydroxymutilin 14-ester
2392009028676211/19/09Pharmaceutical formulations comprising azelastine and a corticosteroid for the treatment of inflammatory or allergic conditions
2402009027560411/05/09M3 muscarinic acetylcholine receptor antagonists
2412009027035510/29/09Compounds
2422009027051010/29/09Glycine transport inhibitors
2432009025390810/08/09Novel m3 muscarinic acetylchoine receptor antagonists
2442009023644509/24/09Fluid dispenser
2452009023984609/24/09Novel compounds
2462009023284709/17/09Immunogenic compositions
2472009022754709/10/09Novel salt form of a beta2-adrenergic agonist quinolin-2-one derivative
2482009022762909/10/09Compounds having activity at the glycine transporter glyt1 and uses thereof
2492009022157709/03/09Compounds having morpholinyl and piperidinyl groups for use as glyt1 inhibitors



ARCHIVE: New 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Glaxo Group Limited in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Glaxo Group Limited with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###

     SHARE